Novartis taps Orionis to pursue 'historically elusive targets'

FierceBiotech | March 06, 2020

Novartis has entered into a four-year research collaboration with Orionis Biosciences. The agreement tasks Orionis with applying its technologies to “historically elusive targets” in multiple therapeutic areas. Orionis has been around since 2015 but kept a low profile over most of that time. The transatlantic biotech used its time flying below the radar to establish two platforms, one focused on cytokines and another for “genome-scale drug discovery,” and to use them to generate a pipeline of preclinical assets targeting different phases of the cancer immunity cycle.

Spotlight

Are you faced with the task of relocating a biospecimen collection? Moving a substantial inventory of samples is a logistical challenge, and requires managing temperature, equipment, regulatory, and personnel safety issues. The choice of vehicle used for transport may be low on the list, but the right truck can be critical to success.

Spotlight

Are you faced with the task of relocating a biospecimen collection? Moving a substantial inventory of samples is a logistical challenge, and requires managing temperature, equipment, regulatory, and personnel safety issues. The choice of vehicle used for transport may be low on the list, but the right truck can be critical to success.

Related News

MEDTECH

Flamingo Therapeutics Expands Alliance with Ionis Pharmaceuticals to Develop RNA-targeted Therapies for Oncology

Flamingo Therapeutics, Inc. | September 09, 2021

Flamingo Therapeutics, Inc., a biotechnology company pioneering RNA-targeting therapies in oncology, today announced that it has entered into an agreement with Ionis Pharmaceuticals to develop RNA-targeted therapies to treat various forms of cancer. This alliance is an expansion of an existing collaboration with Ionis on the FLAME™ discovery engine, following Flamingo's Series A financing in 2020. The agreement and discovery alliance will leverage Flamingo's deep expertise in oncology and long non-coding RNAs (lncRNAs) in combination with Ionis' expertise in RNA-targeted drug discovery and development to advance candidates against targets considered undruggable with traditional approaches. Flamingo's pipeline will include three clinical-stage programs from Ionis, inhibitors of STAT-3, Androgen Receptor (AR) and IRF4, and one preclinical-stage program that targets MALAT1, a well-characterized lncRNA target. Flamingo will also advance its proprietary discovery engine, FLAME (Flamingo LncRNA Antisense Mining Engine), that addresses lncRNAs, a large and untapped class of disease-causing targets within the dark matter of the human genome. "We're thrilled to strengthen our relationship with Ionis who has been at the forefront of RNA-targeted therapy for thirty years," said Michael Garrett, Chief Executive Officer of Flamingo. "We believe the combination of Ionis' leadership in RNA and our cutting-edge lncRNA discovery engine will expand the opportunities for applying RNA-targeted approaches to oncology." "We are pleased that Flamingo is leveraging their core strengths in developing novel cancer medicines to advance innovative Ionis-discovered oncology therapies where there is an unmet need," said Brett P. Monia, Ph.D., Ionis' chief executive officer. In connection with the alliance, Rob MacLeod, Ph.D., VP, Oncology Research & Development of Ionis, will serve as Chief Scientific Officer of Flamingo. Under the terms of the agreement, Ionis is eligible to receive milestone payments and royalties on future product sales of the STAT3, AR, IRF4 and MALAT1 programs. Flamingo retains full rights to its FLAME platform and all lncRNA programs outside of MALAT1. Flamingo Therapeutics was founded by VIB, Ghent University, KU Leuven, the University of Michigan, Kurma Partners and PMV, based on pioneering work led by Professor Jean-Christophe Marine (VIB-KU Leuven), Professor Pieter Mestdagh (Ghent University) and Professor Arul Chinnaiyan (University of Michigan). These scientific teams broke new ground on non-coding RNA genes in cancer and were among the first to show a role for lncRNAs as disease drivers in oncology. About Flamingo Therapeutics Flamingo is pioneering RNA-targeted therapies for oncology with state-of-the art chemistries. Flamingo has the most advanced antisense RNA-targeting oncology portfolio with three clinical programs targeting undruggable transcription factors and splice variants. To support and expand its pipeline, Flamingo has a proprietary discovery engine, FLAME™ (Flamingo LncRNA Antisense Mining Engine), that addresses lncRNAs, a large and untapped class of disease-causing targets within the "dark matter" of the human genome. The Company was founded in 2020 based on pioneering work in the field of lncRNAs in oncology with our academic partners at VIB, KU Leuven, Ghent University and the University of Michigan. Flamingo has a discovery alliance with Ionis Pharmaceuticals and is supported by well-known biotechnology investors Kurma Partners and PMV. The company is headquartered in Belgium with additional operations in San Diego, CA.

Read More

AI

BioMarin and Deep Genomics to Collaborate on Advancing Programs Identified Using Artificial Intelligence

BioMarin | November 18, 2020

BioMarin Pharmaceutical Inc. and Deep Genomics declares that the organizations have gone into a preclinical collaboration that will use Deep Genomics' artificial intelligence drug discovery platform (The AI Workbench) to distinguish oligonucleotide drug applicants in four uncommon sickness signs with high neglected need. Deep Genomics will get an undisclosed forthright installment and is qualified to get improvement achievements as a piece of the coordinated effort. BioMarin will get an elite alternative to get Deep Genomics' privileges to each program for development and commercialization. The organizations didn't uncover financial terms. In the cooperation, Deep Genomics will utilize its AI Workbench to recognize and approve target components and lead competitors, and BioMarin will propel them into preclinical and clinical development. The AI Workbench empowers quick investigation of novel targetable components and restorative up-and-comers. It joins deep learning, automation, progressed biomedical information and huge measures of in vitro and in vivo information to precisely recognize targetable sub-atomic systems and guide the revelation and advancement of oligonucleotide treatments.

Read More

MEDICAL

Alligator Bioscience Announces IND Approval for CD40 Targeting Antibody Mitazalimab

Alligator Bioscience | December 07, 2020

Alligator Bioscience declares an affirmed IND (Investigational new Drug) for the CD40 targeting antibody mitazalimab. IND endorsement by the US Food and Drug Administration (FDA) is an essential to begin clinical preliminaries in the USA. As of late, new benchmark information was distributed indicating that mitazalimab can possibly be top tier in the CD40 field. The comparison demonstrated the potent immune-activating properties and anti-tumor effects of mitazalimab. "While the upcoming clinical Phase Ib/II study in pancreatic cancer, OPTIMIZE-1, will be starting in Europe, the IND opens up for later expansion in the US. This is essential for the future success of the product", said Per Norlén, CEO of Alligator Bioscience.", said Per Norlén, CEO of Alligator Bioscience. "Our key focus right now is to complete the submission of the CTA for start of OPTIMIZE-1 in the EU", he added. The mitazalimab drug candidate has recently reported positive clinical information from a Phase I study performed by Janssen Biotech Inc., showing a manageable safety profile just as early signs of efficacy.

Read More